Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

      
side 1 / 243
Opret nyt indlæg

Darzalex salgstal estimeret 2018 ?
26/5 18:28 peter12 Svar: 0

New Wave Group
17/5 14:18 omardjurhuus Svar: 2

Beregne kurs ud fra nøgletal (
17/5 11:47 PeterS88 Svar: 1

Teva
15/5 16:19 omardjurhuus Svar: 0

TA af Tesla
12/5 13:17 MKHO0001 Svar: 1

Kloge råd til ny invester søges
10/5 17:03 AAndersS Svar: 3

Flot kvartal for Intel
26/4 22:53 Occam Svar: 0

Dara salgstal 2018
15/4 15:41 Vester Svar: 0

Afgivelse af stop-limit ordre med uheldig u..
8/4 10:50 aktiegeek Svar: 3

nøgletal
25/3 11:48 ah1980 Svar: 1

AQR shorts i Genmab
11/3 14:29 peter12 Svar: 3

Tørlast og Allergivacciner i fokus
9/3 11:32 collersteen Svar: 0

Bull markedets fjender.
3/3 12:07 HeyimnotCram Svar: 0

GENMAB - RESUMÈ
22/2 08:12 Helge Larsen/PI-redaktør Svar: 6

Riget fattes penge, Helge sender hatten run..
21/2 13:08 Tyndeejner Svar: 2

GEN - Spørgsmål fra Hollandsk investor
4/2 23:33 Helge Larsen/PI-redaktør Svar: 2

US tax reform udfordrer regnskabsanalyserne.
26/1 01:02 Occam Svar: 2

Zealand Pharma - Kapitalmarkedsdag Københav..
24/1 12:39 Helge Larsen/PI-redaktør Svar: 1

Zealand Pharma announces progress to Phase..
20/1 10:07 Helge Larsen/PI-redaktør Svar: 0

Shalegas og QEC
13/1 13:48 Mcjean Svar: 3

GENMAB Indlæg af ROI (David Mygind)
8/1 13:06 Darvin Svar: 2

Johnson og Johnson
6/1 12:52 MoneyMasterdk Svar: 0

Godt nytår
31/12 17:15 Helge Larsen/PI-redaktør Svar: 5

MYTER OM BITCOIN
29/12 19:48 LetThereBeFire Svar: 2

NUEVOLUTION ANALYSE
22/12 07:53 Helge Larsen/PI-redaktør Svar: 2

ZEALAND PHARMA: Q&A d. 12. december 2017
12/12 19:41 Helge Larsen/PI-redaktør Svar: 0

Torm
8/12 18:58 log Svar: 0

sikker havn
23/11 10:13 Boblefisken Svar: 2

PI aktiekurser
15/11 12:42 CLM 46 Svar: 1

Næst-længste aktie-rally siden 2. verdenskr..
15/11 12:07 TeamGarlic Svar: 0

US Recepttal. Realiseret og Estimeret
15/11 11:56 JørgenVarnæs Svar: 8

Skat af gevinst
10/11 07:08 Jnl Svar: 4

P.E
7/11 19:43 river Svar: 1

Interesse for jobbet som børsmægler
3/11 10:36 WilliamRønde Svar: 2

køb/sælg anbefalinger
2/11 21:03 donprebsi Svar: 4

To sektorer at holde øje med
2/11 09:41 TeamGarlic Svar: 2

Jeg tror Storytell er et rigtig godt køb nu
27/10 14:08 mads007 Svar: 2

Flot indtjening i Intel
26/10 22:34 Occam Svar: 2

Faldende portefølje
25/10 16:44 donprebsi Svar: 6

MoSys Inc. (NASDAQ:MOSY) Købt 0,725
20/10 21:43 ABC123 Svar: 0

IMDZ Immune Design Corp(NASDAQ:IMDZ)
20/10 10:19 ABC123 Svar: 1

ETRM - mulig multibagger på "rent" held
19/10 20:28 ABC123 Svar: 0

WAC- Det rykker vildt herinde
19/10 20:03 ABC123 Svar: 0

TNDM
18/10 20:18 ABC123 Svar: 0

Bont T stores
18/10 17:14 ABC123 Svar: 1

DXTR - Dextera Surgical Inc(NASDAQ:DXTR)
18/10 17:09 ABC123 Svar: 1

Flytning af pension fra TopDanmark Link til..
18/10 15:31 wolf Svar: 1

Brand udsalg på guldmine aktier
17/10 15:23 Nippon1976 Svar: 5

Argentina
15/10 12:32 move Svar: 0

FAO om fødevarer og fiske opdræt
12/10 08:24 nfø Svar: 0


Zealand Pharma announces progress to Phase 3/dasiglucagon

  




Published: 23:30 CET 19-01-2018 /GlobeNewswire /Source: Zealand Pharma / : ZEAL /ISIN: DK0060257814

Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018

Company announcement - No. 4/2018



Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018





Zealand receives FDA approval of its Investigational New Drug (IND) application for its Phase 3 program with dasiglucagon for treatment of congenital hyperinsulinism (CHI)
Two Phase 3 trials are set to start within the coming months at leading centers in the U.S. and Europe
Zealand expects fast development progress to ultimately offer an effective non-surgical treatment for this rare disease affecting neonates and children
U.S. FDA and the European Commission have already granted orphan drug designation for dasiglucagon for the treatment of CHI in 2017



Copenhagen, Denmark, January 19, 2018 - The U.S. Food and Drug Administration (FDA) has approved Zealand's Investigational New Drug (IND) application for initiation of two Phase 3 clinical trials of dasiglucagon in CHI. This positive regulatory milestone and the current clinical evidence enable Zealand to proceed directly into Phase 3 development of dasiglucagon for the treatment of CHI.



CHI is a rare medical condition in neonates and children. Due to a genetic defect in the insulin producing cells, these children are born with too high blood insulin levels, resulting in persistent low blood glucose throughout childhood. Current treatment options are insufficient and the most severely affected children have the pancreas surgically removed within the first months of life in order control the blood glucose levels.



In the Phase 3 program, Zealand will evaluate the potential of chronic dasiglucagon infusions delivered via a pump to prevent hypoglycemia in up to 50 children with CHI and thereby reduce morbidities associated with persistent hypoglycemia as well as neurodevelopmental defects and need for pancreatectomy



Dasiglucagon is a potential first-in-class glucagon analog invented and developed by Zealand. It is stable in aqueous formulation and suitable for pump use and thereby for potential treatment of (CHI). In 2017, the U.S. FDA and the European Commission both granted orphan drug designation for dasiglucagon for the treatment of CHI.



Britt Meelby Jensen, President and CEO of Zealand, comments:

"Congenital hyperinsulinism is a rare and severe disease, which affects newborns and children. I am very pleased with FDA's decision to approve our Phase 3 trials, as it allows us to make fast progression towards a potential treatment that can help these children and possibly save them from surgery with severe lifelong implications"





Dasiglucagon is in development for use in other indications

Dasiglucagon is in development for two additional indications:

Rescue treatment of severe hypoglycemia: Two Phase 3 trials ongoing in patients with type 1 diabetes for treatment in a ready-to-use rescue pen, with results expected in 2018.

Treatment of Type 1 Diabetes in a dual-hormone artificial pancreas pump containing both insulin and glucagon (dasiglucagon), with potential to bring a paradigm shift in treatment. Positive results reported from two Phase 2a studies in 2017, and a Phase 2b proof-of-concept trial is planned for 2018.





For further information, please contact:

Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com



Mats Blom, Executive Vice President, Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com





About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a late stage pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.








04-18_0119_IND_CHI

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Zealand Pharma, Smedeland 36, Glostrup 2600, Danmark
If you would like to unsubscribe and stop receiving these e-mails click here.

Helge Larsen/PI-redaktør 0 76044 20/1 2018 10:07 STEM OP SVAR




side 1 / 243
Opret nyt indlæg